Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12012441 | PMC |
| http://dx.doi.org/10.1093/cvr/cvae266 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cardioprotection with nebivolol in patients undergoing anthracyclines: a randomized placebo-controlled trial.
Cardiovasc Res
April 2025
Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele-Milan, Italy.
Comparison of the Protective Effects of Nebivolol and Metoprolol against LPS-Induced Injury in H9c2 Cardiomyoblasts.
Curr Issues Mol Biol
November 2023
Obesity Research Center, College of Medicine, King Saud University, P.O. Box 2925, Riyadh 11461, Saudi Arabia.
Here, we, for the first time, compared the cardioprotective effects of third-generation vasodilating beta-blocker nebivolol (Neb) and conventional beta-blocker metoprolol (Met) on LPS-induced injury in H9c2 cardiomyoblasts. Our findings denoted that Neb and Met pretreatment diminish LPS-mediated cytotoxicity and oxidative stress. Concomitantly, LPS-triggered inflammatory cytokines activation was significantly suppressed by Neb but not by Met.
View Article and Find Full Text PDFNebivolol in oral subacute treatment prevents cardiac post-ischemic dysfunction in rats, but hyperthyroidism reduces this protection: mechanisms involved.
Naunyn Schmiedebergs Arch Pharmacol
May 2024
Cátedra de Farmacología, Grupo de Farmacología Experimental y Energética Cardíaca (GFEYEC), Departamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata (UNLP), 47 y 115 (1900) La Plata, La Plata, Argentina.
Nebivolol could prevent dysfunction in patients suffering myocardial ischemia. However, influence of hyperthyroidism is not known. Consequences and mechanisms of nebivolol treatment were investigated in isolated hearts from euthyroid (EuT) and hyperthyroid (HpT) rats.
View Article and Find Full Text PDFNebivolol versus placebo in patients undergoing anthracyclines (CONTROL Trial): rationale and study design.
J Cardiovasc Med (Hagerstown)
July 2023
Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan.
Article Synopsis
- The study is about a type of chemotherapy drug called anthracyclines, which can hurt the heart, and it tests a heart-protecting medicine called nebivolol to see if it can prevent this damage.
- It involves patients with breast cancer or a specific type of lymphoma who have healthy hearts and are starting treatment with anthracyclines.
- The trial will compare nebivolol to a placebo (like a fake medicine) over a year to see if it helps protect the heart better than not taking it.
Efficacy and safety of cardioprotective drugs in chemotherapy-induced cardiotoxicity: an updated systematic review & network meta-analysis.
Cardiooncology
February 2023
Department of Medicine, Division of Cardiology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.
Background: Cancer patients receiving chemotherapy have an increased risk of cardiovascular complications. This limits the widespread use of lifesaving therapies, often necessitating alternate lower efficacy regimens, or precluding chemotherapy entirely. Prior studies have suggested that using common cardioprotective agents may attenuate chemotherapy-induced cardiotoxicity.
View Article and Find Full Text PDF